51 results about "Salvianolic acid T" patented technology

The invention relates to a method for increasing the contents of tanshinone and salvianolic acid in a salvia miltiorrhiza hairy root by using a transgene AtMYC2, belonging to the technical field of gene engineering. The method comprises the steps of constructing a high-efficiency expression vector of a plant by using an arabidopsis transcription factor AtMYC2, and carrying out genetic transformation on salvia miltiorrhiza leaves to obtain a gene AtMYC2 overexpressed transgenetic salvia miltiorrhiza hairy root; analyzing the expression of AtMYC2 in the transgenetic salvia miltiorrhiza hairy root and related genes in biosynthetic pathways of tanshinone and salvianolic acid through qRT-PCR; measuring the contents of tanshinone and salvianolic acid in the transgenetic salvia miltiorrhiza hairy root by using a high-performance liquid chromatography (HPLC); and measuring the antioxidant activity of tanshinone and salvianolic acid in the transgenetic salvia miltiorrhiza hairy root by using a DPPH free radical scavenging method. The invention provides the method for simultaneously increasing the contents of tanshinone and salvianolic acid in salvia miltiorrhiza hairy root and also provides a novel high-quality raw material for producing tanshinone and salvianolic acid with important clinic demands so as to have the positive promoting significance and application value for relieving the problem that the drug resources of tanshinone and salvianolic acid are short.

The invention discloses a transgenic method for improving salvianolic acid B content in root of red-rooted salvia, which comprises the following steps of: obtaining cDNA overall length of arabidopsis anthocyanidin generation transcription factor 1 gene through gene cloning; constructing a plant expression vector containing the genes; transforming agrobactrium tumefaciens EHA105 by using the vector so as to obtain an agrobactrium tumefaciens strain containing the genes; transforming the root of red-rooted salvia by using the agrobactrium tumefaciens strain, and culturing to obtain a transgenicplant of the root of red-rooted salvia detected through a polymerase chain reaction; detecting the expression of the arabidopsis anthocyanidin generation transcription factor 1 gene in the transgenicroot of red-rooted salvia through a semi-quantitative reverse transcription-polymerase chain reaction; and performing high performance liquid chromatography on the salvianolic acid B content in the transgenic root of red-rooted salvia subjected to the gene expression, and screening to obtain a transgenic plant of the root of red-rooted salvia with the improved salvianolic acid B content. Due to the obtained transgenic plant of the root of red-rooted salvia, the salvianolic acid B content is 73.27mg/g in dry roots when the transgenic plant of the root of red-rooted salvia grows for 165 days, wherein the salvianolic acid B content is two times of the salvianolic acid B content in non-transformed common dry roots of the root of red-rooted salvia.

The invention discloses a method for extracting salvianolic acid A, which is characterized in that a new process method is adopted to obtain salvianolic acid A extract, the yield of the salvianolic acid A in the salvianolic acid A extract prepared with the method is more than five thousandth, thus saving a great quantity of resources. The invention further discloses a method for preparing the salvianolic acid A, which comprises the steps of adopting a medium pressure liquid phase preparation method, wherein eluent has two phases to carry out isocratic or gradient elution to obtain high-purity salvianolic acid A with related substances, such as salvianolic acid F and salvianolic acid C, with content lower than 0.5 percent. The quality of the salvianolic acid A obtained by using the method is more uniform and more stable.

The invention discloses a method for preparing salvianolic acid A. The method comprises the following steps of: (1), with a substance containing salvianolic acid B as a material, adding an acid substance with weight 0.1-10 times that of the raw material and concentration of 0.01%(v/v)-100%(v/v); adding an organic solvent with weight 0.01-10 times that of the acid substance and boiling point higher than 100 DEG C; heating for 3-5 hours at the temperature of 110-130 DEG C to obtain salvianolic acid A enrichment liquid, wherein the salvianolic acid B accounts for 2%-100% by weight in the substance containing the salvianolic acid B; and (2), cooling the salvianolic acid A enrichment liquid, adding water which is 2-6 times of the enrichment liquid to dilute and purifying to obtain the salvianolic acid A. The method for preparing salvianolic acid A can be used for preventing the salvianolic acid A from oxidizing in a high-temperature aqueous solution, improving the conversion rate of the salvianolic acid B substance, and achieving the material extracting rate of 20%-60%. Meanwhile, the impurity content and purifying difficulty of the final product salvianolic acid A are lowered, so that the prepared salvianolic acid A has purity higher than 90% and can be used for carrying out industrial production well.

The invention discloses a method for effective preparation of a salvianolic acid B extract. The method comprises the steps of: (1) taking Salvia Miltiorrhiza dregs extracted by a 80-100% ethanol solution, adding an ethanol solution with a pH value of 2-8 and an alcohol content of 30-60% to conduct extraction so as to obtain an extracted solution; (2) concentrating the extracted solution to obtain a concentrated solution, and conducting cooling; (3) subjecting the concentrated solution to acid precipitation, carrying out low-temperature standing and solid-liquid separation, thus obtaining a liquid; (4) separating and purifying salvianolic acid B by column chromatography; and (5) carrying out concentration and drying to obtain the salvianolic acid B extract.

The invention discloses a method for preparing total salvianolic acid. The method comprises the following steps of extracting Salvia miltiorrhiza by water-containing low-grade alcohol and extracting headspace polyamide or separating macroporous resin. The method has the advantages that the transferring rate of salvianolic acid B is high and can achieve 50-60%; the loss of active ingredients is low, the quality of the prepared product is good, the content of the total phenolic acid is equal to or greater than 80%, the content of salvianolic acid B is equal to or greater than 50%, and the therapeutic effect is obvious. The invention also discloses a preparation on pharmacy and a preparing purpose thereof.

The medicinal composition of the present invention is compound freeze dried red sage powder for injection comprising red sage extract with salvianolic acid as main component, notoginseng extract with arasaponin as main component, hydroxypropyl beta-cyclodextrin clathrate of borneol and medicinal supplementary material. The preparation process includes extracting red sage component via ultrasonic extraction, ultrafiltering, ethyl acetate extraction and concentration; extracting notoginseng component via water extraction, alcohol precipitation and macro resin adsorption; clathrating borneol to raise its water solubility; and other steps. The present invention is used in preventing and treating cardiac and cerebral vascular diseases and has obvious curative effect.

The invention relates to a method for preparing salvianolic acid A. According to the method, salvia miltiorrhiza extract is prepared from salvia miltiorrhiza medicinal materials and is subjected to vacuum drying, spray drying or microwave vacuum drying after the salvia miltiorrhiza extract is subjected to catalytic conversion and the steps of separation, elution and the like, thereby obtaining the salvianolic acid A. The method for preparing the salvianolic acid A, provided by the invention, is very applicable to industrial application, lower in production cost and novel.

The present invention provides a method for improving stability of salvianolic acid B. The method comprises the steps of: 1) preparing a low eutectic mixture, mixing dried polyol with choline quaternary ammonium salt in a molar ratio of 4-1:1, and heating with stirring at 80-100 DEG C for 6-10 h to obtain a uniform transparent liquid; 2) weighing and dissolving salvianolic acid B in the eutectic mixture, sealing and storing. The salvianolic acid B has good thermal stability (60-90 DEG C) in the eutectic mixture. The present invention overcomes the disadvantages of easy deterioration and degradation of salvianolic acid B during storage in a conventional solvent and high-temperature sterilization, and has great importance on the development and application of salvianolic acid B oral preparations.

The invention relates to a method for preparing salvianolic acid A. According to the method, salvia miltiorrhiza extract is prepared from salvia miltiorrhiza medicinal materials and is subjected to microwave vacuum drying after the salvia miltiorrhiza extract is subjected to catalytic conversion and the steps of separation, elution and the like. The method for preparing the salvianolic acid A, provided by the invention, is very applicable to industrial application, lower in production cost and novel.

The invention provides a detection method of phenolic acid compounds in a compound radix salviae miltiorrhizae tablet, and the detection method comprises the following steps: preparing a standard solution, a reference solution and a to-be-tested product solution, passing through a high performance liquid chromatography for detection; then calculating a relative correction factor of the phenolic acid compounds relative to salvianic acid A sodium; and using a formula IV shown in the specification too obtain the phenolic acid compound content in the compound radix salviae miltiorrhizae tablet. According to the detection method, by detection of one compound (salvianic acid A sodium), simultaneous determination of multiple compounds (salvianic acid A, protocatechuic aldehyde, rosmarinic acid, lithospermic acid and salvianolic acid B) can be realized, and the detection method is simple, rapid, accurate, good in universality, labor, and material and financial resource saving, and can more fully reflect the quality of the compound radix salviae miltiorrhizae tablet.

The invention provides an extraction method of salvianolic acid B. The method comprises the following steps of (1) salvia miltiorrhiza medicinal materials subjected to pretreatment are fed into a super-critical CO2 extraction device; acid water with the pH being 2 to 4 is used as an entrainer to perform super-critical extraction to obtain an extraction solution; (2) the extraction solution obtained in the step (1) is subjected to rotary evaporateion concentration until no water exists to obtain salvianolic acid B. The acid water with the pH being 2 to 4 is used as the entrainer, the salvianolic acid B in the salvia miltiorrhiza medicinal materials is directly extracted out in one step through super-critical CO2 extraction device. The method provided by the invention has the advantages that the extraction efficiency is high; no solvent residue toxicity exists; the extraction separation steps are greatly reduced; the natural active ingredients and heat-sensitive ingredients (salvianolic acid B) cannot be easily decomposed or damaged, the natural features of the extracts can be maintained to the maximum degree, and the selective separation can be realized; the extraction method can be widely applied to natural substance extraction; the problem in the prior art can be effectively avoided.

The invention relates to a method for purifying salvianolic acid A, which comprises the steps of: adjusting the pH of eluate or extract liquid containing salvianolic acid A to 2.5-4.5, and centrifuging; separating supernatant by non-polar or weak-polar macroporous resin column chromatography; eluting with water and then eluting with eluent; carrying out high-efficiency liquid phase detection of salvianolic acid A, and collecting eluate containing salvianolic acid A; separating the obtained eluate with a dextrane gel LH-20 or ODS-C18 or polyamide chromatographic column; eluting with eluent; carrying out high-efficiency liquid phase detection of salvianolic acid A, and collecting eluate containing salvianolic acid A; adjusting the pH of the eluate to 2.0-4.0, extracting the eluate with an organic solvent and separating the organic solvent phase; separating the obtained solution by using a silica gel chromatographic column, eluting with the eluent, carrying out high-efficiency liquid phase detection of salvianolic acid A, and collecting eluate containing salvianolic acid A; recovering the eluent at reduced pressure; and dissolving the eluate with water, and carrying out microwave vacuum drying to further purify salvianolic acid A.

The invention discloses new application of salvianolic acid A as lipoprotein-associated phospholipase A2 (Lp-PLA2) inhibitor. High-fat feeding is combined with VD3 injection and a balloon injury technique to establish a rat atherosclerosis (AS) model, and the influence of the salvianolic acid A on the Lp-PLA2 content and activity of AS rat serum and the influence of the salvianolic acid A on the Lp-PLA2mRNA of an AS rat aorta can be researched. A result shows that the salvianolic acid A can be used for lowering the Lp-PLA2 content and activity of the AS rat serum, and carrying out down regulation on the expression of aorta Lp-PLA2 protein so as to perform an anti-AS function. Meanwhile, human pancreatic cancer BxPC3 nude mouse subcutaneous transplantation tumor model is established, the influence of the SAA (SalvianolicAcid A) of two administration routes on nude mice bearing the Lp-PLA2, cPLA2 and sPLA2 expression can be researched. A result shows that the contents of the Lp-PLA2, the cPLA2 and the sPLA2 in the serum and the tumor tissues and the peri-tumorous tissues of the nude mice bearing the tumor can be obviously lowered. The new application is opened up for the salvianolic acid A, and the salvianolic acid A can be expected to serve as the Lp-PLA2 inhibitor for various medical applications.

The invention provides a method for purifying salvianolic acid A by adopting a normal phase chromatography based on physicochemical properties, chromatographic behaviors and unit separation technology adaptabilities of chemical compositions of salvia miltiorrhiza. A normal phase chromatographic packing is chromatographic silica gel the granularity of which is 100-200 meshes, wherein the normal phase chromatography comprises the following operation steps of: extracting a salvianolic acid A aqueous solution by using ethyl acetate; concentrating ethyl acetate extract liquor until the solid content is 20-30 percent; adding chromatographic silica gel in an amount which is 2-2.5 times that of the salvianolic acid A; putting into a rotatory evaporator for drying at reduced pressure to obtain a flowing solid sample; and putting the solid sample at the top end of a silica gel wet column. A produced prepared with the method has stable and controllable quality and acceptable cost.

The invention relates to the technical field of medicines, discloses novel application of salvianolic acid A, and particularly the application of salvianolic acid A in preparing a medicine for increasing content of CAMP (Cyclic Adenosine Monophosphat) in thrombocyte and/or blood plasma, a medicine for inhibiting activity of phosphodiesterase in thrombocyte, a medicine for promoting activity of adenylate activating enzymes, and a medicine for inhibiting concentration of platelet cytoplasmic calcium, particularly a medicine for preventing or treating thrombolysis and myocardial Ischemia reperfusion injury caused by percutaneous coronary intervention operation or coronary artery bypass grafting and the like.

The invention relates to a pharmaceutical composition for treating cardiovascular and cerebrovascular diseases, specifically to a pharmaceutical composition of hydroxysafflor yellow A and salvianolic acid A, and a kit. The pharmaceutical composition for treating cardiovascular and cerebrovascular diseases comprises hydroxysafflor yellow A and salvianolic acid A. According to the invention, a compound preparation prepared from the hydroxysafflor yellow A and salvianolic acid A monomer or combined appilication of the hydroxysafflor yellow A and salvianolic acid A monomer enables the content of effective components to be effectively increased and impurities in commercially available products to be eliminated, so the current situation that the commercially available products obviously incur anaphylactic reaction is greatly improved. The pharmaceutical composition provided by the invention has substantial curative effect and is applicable to clinical application.